SureTrader Nadex Advertisement SureTrader
Home > Boards > US OTC > Medical - Healthcare >

Oxis International Inc. (OXIS)

Add OXIS Price Alert      Hide Sticky   Hide Intro
Moderator: CashBowski, Tagprofenrir
Search This Board: 
Last Post: 4/28/2017 10:36:17 PM - Followers: 169 - Board type: Free - Posts Today: 0


Oxis International Inc.

Below shows OXS-1550 WORKING - Soon to enter Phase II with FDA!


Treating Non-Hodgkin's lymphoma

OXS-1550 targets cancer cells expressing the CD19 receptor or CD22 receptor or both receptors. When OXS-1550 binds to cancer cells, the cancer cells internalize OXS-1550 and are killed due to the action of drug's cytotoxic payload. OXS-1550 has demonstrated success in early human clinical trials in patients with relapsed/refractory B-cell lymphoma or leukemia.

Treating triple-negative breast cancer

Our lead drug candidate, OXS-2175, is a small molecule therapeutic candidate targeting the treatment of triple-negative breast cancer. In in vitro and in vivo models of TNBC, OXS-2175 demonstrated the ability to inhibit metastasis.

Treating multiple myeloma

Our lead drug candidate, OXS-4235, also a small molecule therapeutic candidate, targets the treatment of multiple myeloma and associated osteolytic lesions. In in vitro and in vivo models of multiple myeloma and osteoporosis, OXS-4235 demonstrated the ability to kill multiple myeloma cells, and decrease osteolytic lesions in bone.



Company Website


Corporate Overview - Presentation
Fall 2015
Click the link:





OXIS Conference Call  March 31, 2015

CEO Interview with The Wolf of Weedstreet




Sean Xie, MD, PhD, EMBA is a tenured Professor at the Department of Pharmaceutical Sciences/Drug Discovery Institute at University of Pittsburgh and Associate Dean for Research Innovation at the School of Pharmacy. He is Principal Investigator of an integrated research laboratory of CompuGroup, BioGroup and ChemGroup, and Founding Director of Computational Chemical Genomics Screening Center. Dr. Xie is also Director/PI of NIH funded National Center of Excellence for Computational Drug Abuse Research. Dr. Xie holds joint faculty positions at the Departments of Computational System Biology and Structural Biology, and Pittsburgh Cancer Institute MT/DD Program. He serves as an invited guest editor for AAPS Journal, Editorial Board of American Journal of Molecular Biology, and Associate Editor of BMC Pharmacology and Toxicology. In 2013, he was named an honorary professor of Chinese Academy of Medical Sciences & Peking Union Medical College. Dr. Xie is a recipient of the 2014 American Association of Pharmaceutical Scientists (AAPS) Outstanding Research Achievement Award.


Dr. James J. Mule, Ph.D. serves as an Executive Vice President and Associate Center Director for Translational Research, the Michael McGillicuddy Endowed Chair for Melanoma Research and Treatment, and the Co-Director of the Donald A. Adam Comprehensive Melanoma Center at the Moffitt Cancer Center. He then moved to Palo Alto, Calif., where he was involved in the birth of two startup companies while an adjunct faculty member in the Department of Surgery, Stanford University. He moved to Ann Arbor, Mich., as the Director of the Tumor Immunology and Immunotherapy Clinical Research Programat the University of Michigan Comprehensive Cancer Center. Dr. Mule is recognized for his translational research studies in cancer immunotherapy. His research group is involved in vaccine strategies and other approaches to stimulate the immune system to recognize and destroy tumors. The work in these areas has helped to develop new treatments for advanced cancer patients. Dr. Mule serves on the Advisory Boards of seven NCI-designated Cancer Centers and was a member of the NCI’s Board of Scientific and Clinical Counselors. He serves as Chair of the Cellular, Tissue and Gene Therapy Advisory Committee of CBER, FDA, is a Special Government Employee of the NCI and the FDA. Dr. Mule is recognized for his research and clinical contributions to cancer immunotherapy, particularly in solid tumors.


Dr. Stephen M. Chang is Vice President-Research & Development at New York Stem Cell Foundation, Chief Scientific Officer at Stemgent, Inc., and Independent Director at MultiCell Technologies, Inc. He is on the Board of Directors at MultiCell Technologies, Inc. Dr. Chang was previously employed as Chief Scientific Officer & Vice President by Canji, Inc., Chief Scientific Officer & Vice President by Schering-Plough Research Institute, and President & Chief Executive Officer by MultiCell Immunotherapeutics, Inc. He also served on the board at Histogen, Inc. He received his undergraduate degree from the University of Michigan and a doctorate degree from the University of California, Irvine.


Dr. Haile has special technical experience in molecular biology, immunology, plant biotechnology, including transgenic plants, cell biology, diagnostics, therapeutics, theranostics, virology, drug delivery systems, host-vector systems, high throughput screening and bioinformatics. She has particular experience with patentability, non-infringement and validity opinions; licensing strategies; FDA counseling; due diligence work in connection with venture capital, private and public financing; mergers and acquisitions in the life sciences industry; and strategic counseling for comprehensive life sciences patent portfolio management. Dr. Lisa Haile concentrates on patent protection.


Information on Multiple Myeloma & Cannabidiol (CBD)

After studying the effects of cannabidiol on multiple myeloma cells, researchers found that; “CBD by itself or in synergy with BORT strongly inhibited growth, arrested cell cycle progression and induced MM cells death by regulating the ERK, AKT and NF-κB pathways with major effects in TRPV2+ cells.”

They conclude that; “These data provide a rationale for using CBD to increase the activity of proteasome inhibitors in MM.”

The study, which validates a recent National Institute of Health study which also found that cannabidiol can inhibit cancer cells, was conducted by researchers at the School of Pharmacy at the University of Camerino in Italy.


Stock Information:

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
OXIS News: Quarterly Report (10-q) 04/28/2017 04:23:56 PM
OXIS News: Information Statements (revised) (prer14c) 04/24/2017 05:30:49 PM
OXIS News: Information Statements (revised) (prer14c) 04/14/2017 01:07:47 PM
OXIS News: PURA - BUY Recommendation Stands On Very Bullish Rating 04/06/2017 12:18:22 PM
OXIS News: PURA - American Bulls Issues BUY Recommendation 04/05/2017 08:30:00 AM
News News Alert: Quarterly Report (10-q) 04/28/2017 04:23:56 PM
#9588  Sticky Note The topic of this board is OXIS. The CashBowski 03/31/17 11:03:34 AM
#10470   Dont touch this, it is a reverse split munimi 04/28/17 10:36:17 PM
#10469   6000 ticketsymbols were halted today, there was a Box Money 04/28/17 05:25:34 PM
#10468   10Q out, dilution monster whoooooah sweet assets.... NOT chico hombre2 04/28/17 04:32:09 PM
#10467   The RS isn't listed on Finra daily list, CashBowski 04/28/17 01:25:57 PM
#10466   There's currently 360 OTC tickers in a U3 CashBowski 04/28/17 11:19:25 AM
#10465   Thank you! Mbrew34 04/28/17 11:18:24 AM
#10464   R/S occuring JayP-Diddy 04/28/17 11:16:50 AM
#10463   Oxis halted? Mbrew34 04/28/17 10:40:20 AM
#10462   Just like MCET there's nothing left to believably simon wagstaff 04/27/17 06:37:29 PM
#10457   the posts here are now more realistic OxisWatcher 04/25/17 03:48:31 PM
#10456   Once they get the reverse split done and scoot27 04/25/17 02:13:43 PM
#10455   Mkt Cap=2.21M, price=0.018, 2.21/.018=123M. chromaticity 04/25/17 12:39:39 PM
#10454   Outstanding is 436,058,326 per revised 14c Gibba 04/25/17 12:14:37 PM
#10453   thanx for the data... Fibanotch 04/25/17 12:08:05 PM
#10452   The approval of an amendment to our certificate chromaticity 04/25/17 12:00:44 PM
#10451   R/S ,,, When ? this quarter or next ...Anyone Fibanotch 04/25/17 11:22:30 AM
#10450   so sorry OXIS will never go .021 b/c chromaticity 04/21/17 11:26:57 AM
#10448   Ok I took a look on it her jimbosskow 04/20/17 05:52:52 PM
#10447   Thanks for your input. I do appreciate OxisWatcher 04/20/17 03:50:03 PM
#10446   I'm waiting on the RS and the downtrend jimbosskow 04/20/17 12:40:10 PM
#10445   You didn't ask me, but I think I simon wagstaff 04/20/17 12:30:15 PM
#10444   Do you have a prediction on how high OxisWatcher 04/20/17 12:10:53 PM
#10443   MCET demonstrated that it's difficult mathematically to have simon wagstaff 04/20/17 11:50:07 AM
#10442   R/S is horrible chromaticity 04/20/17 11:30:30 AM
#10441  Restored really don't need r/s if management has confidence. chromaticity 04/19/17 10:31:23 PM
#10439   Waiting on it... patiently... jimbosskow 04/19/17 08:44:16 PM
#10438   Only a pump and dumper would claim this scoot27 04/19/17 07:42:03 PM
#10436   Good luck to you. OxisWatcher 04/19/17 04:35:07 PM
#10435   I am going to attempt to weather the storm. King_Solomon 04/19/17 04:19:30 PM
#10434   R/S A STUPID MOVE !!! Livelikenotommorow 04/19/17 03:50:29 PM
#10432   Not true BondAssets 04/19/17 12:33:39 PM
#10431   No you are wrong again BondAssets 04/19/17 12:20:06 PM
#10430   This is getting to be just like MCET. simon wagstaff 04/19/17 12:19:41 PM
#10427   They most certainly are. The phase II was simon wagstaff 04/19/17 11:17:55 AM
#10425   You make your money from inactivity. BondAssets 04/19/17 10:59:16 AM
#10424   No they are not BondAssets 04/19/17 10:58:15 AM
#10423   1. Anyone have a prediction for when R/S OxisWatcher 04/19/17 10:54:12 AM
#10422   All of the things that are posted over simon wagstaff 04/19/17 08:06:47 AM
#10421   Oxis cured the cancer for a lady :) BondAssets 04/19/17 07:17:56 AM
#10419   Once it hits the Nasdaq it will sky BondAssets 04/19/17 04:22:54 AM
#10418   It will be just fine :) Oxis cured BondAssets 04/19/17 04:21:27 AM
#10417   This is a NO BUY before R/S. Gibba 04/18/17 10:17:01 PM
#10416   Reverse split is going to kill this stock, all4weed 04/18/17 10:00:21 PM
#10415   Oxis Announces Treatment of First Patient in FDA BondAssets 04/18/17 06:09:38 PM
#10414   No it is way undervalued :) BondAssets 04/18/17 04:43:48 PM
#10413   this is already priced into the current share price. OxisWatcher 04/18/17 04:36:17 PM
#10412   Oxis cured a ladies cancer :) BondAssets 04/18/17 04:10:25 PM
#10411   A most amusing day! simon wagstaff 04/18/17 03:55:22 PM
#10407   Thank you my friend.. Davnet01 04/18/17 03:26:11 PM
#10405   Oxis International Inc. Announces Approval of FDA Phase BondAssets 04/18/17 03:18:13 PM